A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Pyridorin (Pyridoxamine Dihydrochloride) in Subjects With Nephropathy Due to Type 2 Diabetes

Trial Profile

A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Pyridorin (Pyridoxamine Dihydrochloride) in Subjects With Nephropathy Due to Type 2 Diabetes

Discontinued
Phase of Trial: Phase III

Latest Information Update: 28 Oct 2016

At a glance

  • Drugs Pyridoxamine (Primary)
  • Indications Diabetic nephropathies; Renal failure
  • Focus Registrational; Therapeutic Use
  • Acronyms PIONEER
  • Sponsors NephroGenex
  • Most Recent Events

    • 08 Mar 2016 Status changed from recruiting to discontinued, as reported by ClinicalTrials.gov.
    • 21 Jan 2016 According to a NephroGenex media release, an independent Data and Safety Board (DSMB) has completed the second pre-planned safety review and has recommended continuation of this trial as planned.
    • 13 May 2015 According to NephroGenex media release, the European Medicines Agency indicated that this trial may be adequate to support a Marketing Authorization Application in Europe.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top